


PHARMACEUTICAL 2018

Myovant Sciences Ltd. Rank 161 of 349





PHARMACEUTICAL 2018

Myovant Sciences Ltd. Rank 161 of 349

The relative strengths and weaknesses of Myovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Myovant Sciences Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 368% points. The greatest weakness of Myovant Sciences Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -152%, being 125% points above the market average of -278%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 184,164 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 18,337 |
| Liabilities, Non-Current | 0 |
| Other Assets | 208 |
| Other Compr. Net Income | 140 |
| Other Expenses | 27,583 |
| Other Liabilities | 165 |
| Other Net Income | 0 |
| Property and Equipment | 906 |
| Research and Development | 43,500 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 12,357 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 185,278 |
| Liabilities | 18,502 |
| Expenses | 83,440 |
| Stockholders Equity | 166,776 |
| Net Income | -83,440 |
| Comprehensive Net Income | -83,370 |
| Economic Capital Ratio | -152% |